Biotech Co.* (Country; Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date)
JUNE
Ascenta Therapeutics Inc.* Sanofi-Aventis SA (France) Collaboration for an early stage cancer program that include two preclinical candidates designed to target the p53 protein The deal includes up to $398M in up-front and milestone payments, plus tiered royalties on any products that make it to market (6/7)
Diamyd Medical AB (Sweden; PK:DMYDY) Ortho-McNeil-Janssen Pharmaceuticals Inc. (unit of Johnson & Johnson) Deal to develop and commercialize its recombinant glutamic acid decarboxylase-65 antigen-based immunotherapy to treat and prevent Type I diabetes Ortho-McNeil is paying Diamyd $45M up front, plus up to $580M in development and sales milestone payments; the companies will equally share development costs, and it includes royalties (6/23)
Durect Corp. (DRRX) Hospira Inc. Deal to develop and market Posidur The companies will jointly fund remaining development costs, and Hospira holds commercialization rights in the U.S. and Canada; Hospira will make an up-front payment of $27.5M and could pay up to $185M in milestone payments, as well as a royalty on product sales (6/9)
Dyax Corp. (DYAX) Sigma-Tau SpA (Italy) Partnership to develop and commercialize ecallantide to treat hereditary angioedema throughout Europe, North Africa, the Middle East and Russia Sigma Tau will pay Dyax $2.5M up front and will purchase $2.5M in equity shares at a 50% premium above market value; Dyax also is eligible for more than $100M in development and sales milestones, and royalties equal to 41% of net sales (6/22)
Eisai Inc. (FSE:EII) Helsinn Healthcare SA (Switzerland) Licensing agreement for U.S. commercialization rights to its fixed-dose combination product in both oral and IV forms containing netupitant and palonosetron, which is under investigation to prevent chemotherapy-induced nausea and vomiting No financial terms were disclosed (6/10)
EnGen Bio Inc.* Dyadic International Inc. Nonbinding term sheet for an outlicense on an exclusive worldwide basis of Dyadic's C1 platform technology Dyadic is eligible to receive a substantial equity stake in EnGen Bio (6/10)
Essen BioScience Inc.* Nycomed A/S (Switzerland) Joint discovery agreement to identify small-molecule ion channel modulators as pain therapeutics The companies will collaborate to screen, optimize and develop modulators of voltage-gated ion channels (6/22)
Metabolex Inc.* Ortho-McNeil-Janssen Pharmaceuticals Inc. (unit of Johnson & Johnson) Deal to discover and develop compounds for Type II diabetes and other disorders Metabolex will receive an undisclosed up-front payment and could be eligible to receive development, regulatory and commercial milestones up to $330M; Metabolex also is eligible for royalties (6/23)
Neurocrine Biosciences Inc. (NBIX) Abbott Exclusive worldwide deal to develop and commercialize elagolix to treat endometriosis-related pain The deal is worth more than $575M, including $75M up front (6/17)
Neurocrine BioSciences Inc. (NBIX) Boehringer Ingelheim GmbH (Germany) Research and development deal for small-molecule GPR119 agonists to treat Type II diabetes and other indications using Neurocrine's technology platform SiNERG The deal is worth more than $235M, including $10M up front, plus royalties (6/18)
OncoMed Pharmaceuticals Inc.* Bayer Schering Pharma AG Deal to develop drugs targeting the Wnt signaling pathway An agreement that brings $40M up front, with the potential for more than $1B in future milestones; the deal calls for up to five compounds and up to $387.5M per biotherapeutic, or up to $112M per small molecule, in development, regulatory and sales milestones, plus double-digit royalties and certain co-development options (6/18)
Orexo AB (Sweden; SSE:ORX) Ortho-McNeil-Janssen Pharmaceuticals Inc. and Janssen Pharmaceutica NV Alliance to develop two of its preclinical programs that target pathways involved in arachidonic acid metabolism Orexo will get an up-front payment of $10M and will get another $11.5M in research funding (6/2)
Regulus Therapeutics Inc.* Sanofi-Aventis Group SA (France) Partnership aimed at discovering microRNA-based drugs against four fibrosis targets The deal is worth $750M, including $25M up front, as well as a $10M equity investment, plus $650M in milestone payments and royalties (6/23)
Saladax Biomedical Inc.* Bristol-Myers Squibb Co. Multiyear development and commercialization agreement for the development of certain clinical diagnostic tests to be used in conjunction with the development of certain therapeutic compounds in the BMS pipeline Companies will collaborate globally on development and regulatory approvals; Saladax received exclusive global rights to commercialize the assays it develops (6/22)
BioWa Inc.* GlaxoSmithKline plc (UK) Two agreements, one amending a 2007 deal to provide GSK with extended access to BioWa's Potelligent Technology platform for research, development and commercialization of antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity The second agreement provides GSK with access to BioWa's Complegent Technology for enhancing the complement-dependent cytotoxicity of select GSK therapeutic antibodies; BioWa will receive up-front and annual fees, development milestone payments and royalties on any marketed products (6/24)
Entelos Inc.* Pfizer Inc. Nonexclusive, perpetual license that gives access to Entelos' Metabolism Physiolab platform The platform is designed to combine physiology and individual behavior to support research on obesity and diabetes (6/25)
miRagen Therapeutics Inc.* Santaris Pharma A/S (Denmark) Alliance to develop microRNA-targeted medicines to treat cardiovascular disease MiRagen will gain access to Santaris' Locked Nucleic-Acid platform to develop and commercialize single-stranded LNA-based product; Santaris will receive a minority equity interest in miRagen and is eligible for undisclosed milestone payments plus royalties (6/24)
TransTech Pharma Inc.* Forest Laboratories Inc. Partnership to develop and commercialize a new class of glucose-lowering agents to treat diabetes TransTech is receiving a $50M up-front payment and is eligible to receive royalties on worldwide sales; Forest is responsible for all development and commercialization costs (6/9)
Tranzyme Pharma Inc.* Norgine BV (the Netherlands) Exclusive rights agreement to develop and commercialize Tranzyme's ghrelin agonist, ulimorelin, in several ex-U.S. regions Norgine gains rights to the Phase III compound, being developed in gastrointestinal dysmotility conditions in acute care settings, in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa; Tranzyme retains development rights in the U.S. and Asian countries; Norgine also will make an undisclosed equity investment in Tranzyme (6/17)
Vivalis SA (France; Paris:VLS) Sanofi-Aventis Group (France) License agreement for the Humalex antibody platform Vivalis will receive an up front payment of $3.6M, plus another potential €35M in milestone payments, as well as royalties (6/9)
WisTa Laboratories Ltd.* (subsidiary of TauRx Pharmaceuticals) Bayer Schering Pharma AG (Germany) Collaboration to develop specific markers designed to aid in the diagnostics and management of tau protein-related Alzheimer's disease using brain-imaging technology TauRx will use its technology platform of ligands, specialized tau-directed assays and its animal models to optimize the development of ligands; diagnostic products arising from the deal will be developed by Bayer, while compounds with therapeutic potential will be developed by TauRx (6/4)
Notes:
# The information in the chart does not cover agricultural agreements or those between biotech companies.
The date indicated refers to the BioWorld Today issue in which the news item can be found.
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
FSE = Frankfurt Stock Exchange; PK = Pink Sheets; SSE = Stockholm Stock Exchange.